Veraxa Biotech (VRXA) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Veraxa Biotech (VRXA) over the past year, losing 7.5% versus a loss of 88.5%. Yarrow Bioscience is the larger company by market cap ($184.9 million vs $154.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VRXA | YARW |
|---|---|---|
| Share price | $1.09 | $19.87 |
| Market cap | $154.13M | $184.88M |
| 1-day change | -9.17% | +5.83% |
| YTD return | -88.75% | -35.26% |
| 1-year return | -88.53% | -7.51% |
| 5-year return | — | -98.29% |
| EPS (TTM) | $-0.57 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.36 | $46.95 |
| 52-week low | $1.04 | $16.05 |
| Distance from 52-week high | -96.02% | -57.68% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +186.86% |
| Average volume | 274.75K | 87.51K |
| Shares outstanding | 141.41M | 9.30M |
| Employees | — | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed VRXA by 81.0 percentage points over the past year.
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
VRXA vs YARW FAQ
Which is bigger, Veraxa Biotech or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $184.88M compared with $154.13M for Veraxa Biotech (VRXA).
Which stock has performed better over the past year, VRXA or YARW?
YARW returned -7.51% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Veraxa Biotech and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.